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Background: Subsequent entry biologics (SEBs) may soon be a reality in Canadian nephrology practice.
Understanding the worldwide experience with these agents will be valuable to Canadian clinicians.
Objectives: To compare the efficacy and safety data between SEBs used in nephrology practice and their reference
biologic.
Design: Systematic review.
Sources of information: Ovid MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Database of Abstracts
of Review of Effects, Cochrane Central Register of Controlled Trials.
Patients: Adult patients with chronic kidney disease (CKD).
Methods: Our systematic review follows the process outlined by Cochrane Reviews. For efficacy data, all
randomized controlled trials (RCTs), quasi-RCTs and observational trials in nephrology practice were included. For
safety data, case series, case reports, review articles in nephrology practice and pharmacovigilance programs were
included as well.
Results: Only epoetin SEBs trials were published in the literature. Ten studies involving three different epoetin SEBs
(epoetin zeta, HX575 and epoetin theta) were included. The mean epoetin dose used did not differ significantly
between the SEBs and the reference product. For epoetin zeta and epoetin theta, the mean hemoglobin levels
achieved in the studies were similar between the SEBs and the reference epoetin. The HX 575 studies reported a
mean absolute change in hemoglobin within the predefined equivalence margin, when compared with the
reference biologic. In terms of safety data, 2 cases of pure-red-cell aplasia were linked to the subcutaneous
administration of HX 575. Otherwise, the rate of adverse drug reactions was similar when epoetin SEBs were
compared with the reference biologic.
Limitations: Our analysis is limited by the paucity of information available on SEB use in nephrology with the
exception of epoetin SEBs. Methodological flaw was found in one of the epoetin zeta studies which accounted for
45% of pooled results.
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Conclusions: Little clinical difference was found between epoetin SEBs and the reference product. Although not
deemed clinically important, the financial implication of a possible dose difference between epoetin zeta and
reference product should be considered in pharmacoeconomic studies. Ongoing trials are expected to address the
risk of pure-red-cell aplasia with HX 575.
Keywords: Subsequent entry biologic, Rituximab, Darbepoetin, Tissue plasminogen activator, Epoetin alpha, Epoetin
beta, Epoetin zeta, HX 575, Epoetin thetaAbrégé
Contexte: Il est possible que les produits biologiques ultérieurs (PBU) soient bientôt utilisés en néphrologie. Afin de
guider la pratique en néphrologie au Canada, il est important de comprendre l’ensemble des expériences
produites, à l’échelle mondiale, en matière d’efficacité et d’innocuité de ces agents.
Objectifs: Comparer les données relatives à l’efficacité et l’innocuité entre les PBU utilisés en néphrologie et leurs
médicaments biologiques de référence.
Type d’étude: Revue systématique.
Sources de données: La recherche en vue de la revue de littérature a été effectuée en interrogeant les bases de
données suivantes : Ovid Medline, Embase, la base de données de revues systématiques Cochrane Reviews, la
Database of Abstracts of Reviews of Effects, et la Cochrane Central Register Controlled Trials.
Patients: Les patients d’âge adulte atteints de néphropathie chronique.
Méthodes: Notre revue systématique suit la méthode suggérée par la Collaboration Cochrane (Cochrane Reviews).
Pour les données se rapportant à l’efficacité, l’ensemble des essais randomisés contrôlés (ERC) et des modèles quasi
expérimentaux et des études observationnelles du domaine de la néphrologie ont été comptabilisés. Pour les
données se rapportant à l’innocuité, tous les ERC, les modèles quasi expérimentaux, les études observationnelles, les
études ou séries de cas, ainsi que les revues d’articles en néphrologie clinique et de programmes en
pharmacovigilance ont été comptabilisés.
Résultats: Nous nous sommes attardés à l’époétine biologique ultérieure, puisqu’aucune documentation sur
d’autres produits biologiques ultérieurs (PBU) n’était disponible. Nous avons utilisé dix études présentant trois
époétines biologiques ultérieures différentes (époétine zeta, époétine HX575 et époétine thêta). Il n’existait pas de
différence significative entre les doses moyennes des PBU et d’époétine biologique de référence. La dose moyenne
d’époétine utilisée ne variait pas de façon significative entre les PBU et le produit de référence. Pour les époétines
zeta et thêta, les taux moyens d’hémoglobine obtenus dans les diverses études entre les PBU et les époétines de
référence étaient similaires. Les études se rapportant à l’époétine HX575 montraient un changement absolu du taux
moyen d’hémoglobine à l’intérieur de l’intervalle d’équivalence prédéfini, lorsque comparé au médicament
biologique de référence. En ce qui concerne les données d’innocuité, deux cas d’érythroblastopénie chronique
acquise ont été liés à l’administration sous-cutanée de l’époétine HX575. Sinon, les taux d’effets indésirables
recensés pour l’époétine biologique ultérieure et son médicament biologique de référence étaient similaires.
Limites de l’étude: Notre analyse est limitée par la rareté de l’information accessible sur l’utilisation des PBU en
néphrologie, à l’exception de l’époétine biologique ultérieure. Une faille sur le plan méthodologique a été retrouvée
dans une des études sur l’époéine zeta. Celle-ci se rapportait à 45 % des résultats regroupés.
Conclusions: Peu de différences sur le plan clinique ont été trouvées entre l’époétine biologique ultérieure et
l’époétine de référence. Même si elles ne sont pas cliniquement significatives, les répercussions financières qui sont
entraînées par la possible différence de dose entre l’époétine zeta et le produit de référence devraient être
considérées dans les études pharmacoéconomiques. Il existe certaines préoccupations entourant les risques
d’érythroblastopénie chronique acquise et l’époétine HX575, mais des essais présentement en cours tentent de faire
le tour de la question.
(Continued on next page)
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What was known before: SEBs pertinent to nephrology practice are available commercially in other countries.
Epoetin SEBs have been compared with reference epoetins in clinical studies involving CKD patients.
What this adds: This systematic review summarizes the efficacy data comparing epoetin SEBs to the reference
epoetins in patients with CKD and provides an overview of the European experience in terms of safety data for
epoetin SEBs. No other SEBs pertinent to nephrology practice have published data as yet.Why this report is important?
Subsequent entry biologics (SEBs) may soon be a reality
in Canadian nephrology practice. A critical evaluation of
the SEB trials will enable the Canadian nephrology com-
munity to make important decisions regarding the safe
and effective use of these agents.
Key messages
Little clinical difference was found between epoetin SEBs
and the reference product; however, a non-clinically im-
portant dose difference between epoetin zeta and refer-
ence product should be noted. Pure-red-cell aplasia has
been reported with the subcutaneous administration of
HX 575.
Implications for future research
Pharmacoeconomic studies should be conducted to as-
sess the financial implication of a possible dose differ-
ence between epoetin zeta and reference product. Post-
marketing surveillance is needed to provide a more pre-
cise estimate of pure-red-cell aplasia frequency and to
establish the overall adverse reaction profile of all epoe-
tin SEBs in clinical practice. Studies are needed for SEBs
of other biologics commonly used in nephrology prac-
tice, such as darbepoetin, tissue plasminogen activator
and rituximab.
Introduction
Biologic medicines have contributed to the health of
Canadians since the 1980s. In nephrology, erythropoiesis
stimulating agents (ESAs), a biologic drug, have been the
cornerstone of renal anemia treatment since epoetin
alpha was marketed in the 1980s [1]. As patents expire
for many of these products within this decade, subse-
quent entry biologics (SEBs), or the “generic” of the in-
novator biologic, will be entering the Canadian market.
For example, the Canadian patent for epoetin alpha ex-
pired in May 2014 and epoietin SEBs are expected to
enter the Canadian market within the next year. They
bring the opportunity to reduce health care costs, but
pose unique challenges. Even if SEBs are highly similar
to the innovator product, the small differences have the
potential to translate into clinical differences in efficacy,
safety and immunogenicity [2]. To improve our under-
standing around these new drugs, which might be availableon the Canadian market in a near future, we conducted a
systematic review with the following objectives:
1. To compare the efficacy data between SEBs used in
nephrology practice and their reference biologic
2. To compare the safety data between SEBs used in
nephrology practice and their reference biologic with
regards to expected side effects (common or rare)
3. To summarize any unexpected side effects reported
in the literature and pharmacovigilance programs for
SEBs used in nephrology practice
Methods
This systematic review follows the process outlined by
Cochrane Reviews.
Types of studies
For efficacy data, all randomised controlled trials (RCTs),
quasi-RCTs and observational trials in nephrology prac-
tice were included. For safety data, all randomised con-
trolled trials (RCTs), quasi-RCTs, observational trials, case
series, case reports, review articles in nephrology practice
and pharmacovigilance programs were included.
Types of participants
For efficacy and safety data, adult and pediatric patients
with CKD were included.
Types of interventions
All trials evaluating the use of any SEBs were included,
whether the intervention was tested on its own or head-
to-head with the reference biologic. Specifically, a com-
prehensive literature search was conducted for SEBs of




4. tissue plasminogen activator (tPA)
Search methods for identification of studies
Relevant articles were obtained from Ovid MEDLINE
<1946-2013 December 06 > and EMBASE <1974 to 2013
December 06 > electronic sources using the search terms
biosimilar pharmaceuticals, subsequent entry biologics
Table 1 Summary of biosimilar epoetins marketed in the
European Union
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darbepoetin, rituximab, and tissue plasminogen activator.
In addition, the following databases were searched using
the same search terms: Cochrane Database of Systematic
Reviews (2005 to December 2013); Database of Abstracts
of Review of Effects (December 2013); Cochrane Central
Register of Controlled Trials (December 2013). The refer-
ence lists of review articles and relevant trials were also
used to identify additional clinical trials. There was no lan-
guage restriction.Figure 1 Results of a literature review performed to identify clinical tData collection and analysis
The search strategies described above were used to ob-
tain titles and abstracts of studies that might be rele-
vant to this review. The titles and abstracts, and full
text when necessary, were screened independently by
J.G.M. and M.L., who excluded studies that were not ap-
plicable based on the above inclusion criteria; however,
studies and reviews that potentially included relevant data
or information on trials were included for full-text screen-
ing. Data extraction was carried out by the same reviewers
using standardized Cochrane data extraction format. It
was planned that studies reported in non-English language
journals (if any) would be translated before assessment.
Where more than one publication of one trial existed,
only the publication with the most complete data was in-
cluded. Disagreements were resolved by consensus be-
tween the two reviewers.
Study quality
The quality of included studies was assessed independ-
ently by the same two reviewers, without blinding to
authorship or journal, using the checklist developed by
the Cochrane Group [3]. Discrepancies were resolved by
consensus. The quality items assessed included allocationrials involving epoetin SEBs.
Table 2 Summary of the studies included in the systematic review
Authors (year) Design Population Enrolment Intervention Follow-up Outcomes
HX 575
Haag-Weber et al. 2009 [15] R DB multicentre
parallel group
equivalence study
HD patients I: 314 C: 164 HX 575 vs. Epoetin alpha
IV at a 1:1 dose
conversion
56 weeks 1: Occurrence of anti-Epoetin Abs and the evaluations of ADR
Haag-Weber et al. 2012 [16] RCT DB CKD Stage 3-4 I: 175 C: 163 HX 575 SC 75 IU/kg/
week vs. Epoetin alpha
SC 75 IU/kg/week
26 weeks 1: Occurrence of anti-Epoetin Abs and the evaluations of ADRs
Stopped early due to safety issue





I: 745 HX 575 IV 3 times/week 26 weeks 1: Occurrence of anti-Epoetin Abs and the evaluations of ADRs
Epoetin zeta
Baldamus et al. 2008 [12] Multicentre non-
controlled, follow-up






1: Occurrence of anti-Epoetin Abs and the evaluations of ADRs
Krivoshiev et al. 2008 [8] RCT DB multicentre HD patients I:305 C:304 Epoetin zeta IV 1–3
times/week vs. Epoetin
alpha IV 1–3 times/week
24 weeks 1: Dose of epoetin/kg /week; Hb during the last 4 weeks of
treatment; proportion of patients with treatment success, increase in
Hb over time, proportion of patients with maintenance success, Hb
during each 4-week interval, proportion of patients with an increase
in Hb of > 1 g/dL for 4 weeks, percentage of Hb > 10 g/dL,
percentage of HCT measurements > 30%, proportion of patients
needing blood transfusion
Krivoshiev et al. 2010 [9] RCT DB multicentre HD patients I: 232 C: 230 Epoetin zeta SC vs.
Epoetin alpha SC
28 weeks 1: Dose of epoetin/kg/week; Hb during the last 4 weeks of treatment;
mean HCT; proportion of patients with any permanent or transient
changes in Hb > 1 g/dL; proportion of patients with any permanent
or transient dose change; proportion of patients with any Hb outside
the target range; incidence of blood transfusion
Lonneman et al. 2011 [10] Observational single
centre
HD patients I: 18 Epoetin zeta IV 26 weeks 1: Dose of epoetin/kg/week ;Hb during the last 4 weeks of treatment;
incidence of Hb > 13 g/dL, the ratings of local and general tolerability,
the occurrence of anti-EPO Abs and evaluation of ADRs
Wizemann et al. 2008 [11] DB cross-over study
multicentre
HD patients I: 155 C:158 Epoetin zeta IV 1–3
times/week and Epoetin
alpha IV 1–3 times/week
12 weeks x 2 1: Dose of epoetin/kg/week; Hb during the last 4 weeks of treatment;
HCT levels; proportion of patients with any permanent or transient
changes in Hb > 1 g/dL; proportion of patients with any permanent
or transient dose change; proportion of patients with any Hb
measurement outside the target range; incidence of blood transfusion
Epoetin theta




HD patients I:180 C: 90 Epoetin theta IV vs.
Epoetin beta IV; 1:1
dosage conversion

















Table 2 Summary of the studies included in the systematic review (Continued)






I: 193 C: 95 Epoetin theta SC 1 time/
week vs. Epoetin beta
SC 1 time/week
26 weeks 1: Change in Hb from baseline to end of treatment
R = randomized; DB = double-blind; HD = hemodialysis; I = Intervention; C = Control; IV = intravenous; SC = subcutaneous; 1: Study primary outcome; Abs = Antibodies; ADRs = Adverse drug reactions; RCT = Randomized
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outcome assessors, intention-to-treat analysis, and the
completeness of follow-up.
Statistical assessment
Results were expressed as a risk ratio (RR) with 95% con-
fidence intervals (CI) for all categorical outcomes of the
individual studies. Data were pooled using random effects
and fixed effects models. Where continuous scales of
measurement were used to assess the effects of treat-
ment (epoetin dose used, hemoglobin values), the mean
difference (MD) was used. Heterogeneity was analysed
using a chi-squared test on N-1 degrees of freedom,
with an alpha of 0.05 used for statistical significance
and the I2 statistic. I2 values of 25%, 50% and 75% repre-
sent low, medium and high levels of heterogeneity. Sub-
group analyses were planned to explore how possible
sources of heterogeneity (hemodialysis versus non-dialysis
CKD population, intravenous versus subcutaneous admin-
istration) might influence treatment effect. It was also
planned that if sufficient RCTs were identified, an attempt
would be made to assess funnel plot asymmetry due to
small study effect, as this may be indicative of publication
bias. Results are presented for each individual SEB.
Results
No published clinical trials involving darbepoietin, ri-
tuximab or tPA were identified. As of December 2013,
18 human clinical trials involving SEB rituximab are re-
gistered with European Medicines Agency Clinical Trial
Register (EUDRACT) or with the National Institute of
Health at Clinicaltrials.gov [4,5]. Of these, 11 trials are
conducted in patients with rheumatoid arthritis and seven
in patients with hematological malignancies. Nine are
already in phase III comparing the rituximab SEBs to the
innovator product with four being open label extension
trials evaluating efficacy and/or safety parameters. None
of these trials has published preliminary results. Two of
the rheumatoid arthritis trials (TL011 by TEVA and
SAIT101 Samsung Biologics) and two oncology trials
(MK8808 by Merck & Co. and CT-P10 by Celltrion)
were halted prematurely, while two Sandoz trials involving
GP-2013 have not had any updates on the Clinicaltrial.govFigure 2 Mean epoetin dose used in studies comparing epoetin zetawebsite for over two years. Exact reasons for early termin-
ation of the mentioned studies have not been given.
Currently, two biosimilar molecules of epoetin alpha
are available on the European market: epoetin zeta and
HX575 [6]. Although developed as a stand-alone prod-
uct, epoetin theta is clinically considered to be a biosimi-
lar by many authors [7]. Table 1 provides the chemical
denominations and brand names of the biosimilar epoe-
tins marketed in EU. Since this review summarizes clinical
outcomes related to biosimilar ESAs, results on epoetin
theta have been incorporated into our report. The litera-
ture search retrieved 131 reports of SEB epoietin, of which
120 were excluded. Analysis of the 11 remaining articles
identified 12 studies published in 12 articles which were
analysed in full-text: four studies (2147 patients) were
on epoetin zeta, three studies (2510 patients) were on
HX575, and two studies (557 patients) were on epoe-
tin theta. The search results are summarized in Fig-
ure 1. Reasons for exclusion of studies included non-
CKD topics, duplicate reports, case reports, abstracts
or methodology used that precluded analysis. A sum-
mary table of the included studies is presented at
Table 2.
1. Characteristics of studiesand rFive clinical trials involving epoetin zeta were
identified: two RCTs [8,9], one observational [10],
one cross-over [11], and one long-term follow-up
[12]. Two studies were excluded: a case report and a
post-hoc analysis [13,14]. Of the comparison trials,
three compared epoetin zeta to epoetin alpha
[8,9,11] and one compared epoetin zeta to other
ESAs after a switch-over [10]. All but one trial
evaluated intravenous administration [8,10-12];
Krivoshiev 2010 evaluated subcutaneous route of
administration [9]. All studies were conducted in
hemodialysis patients.
Three clinical trials involving epoetin HX575 were
identified: two RCTs [15,16] and one prospective
single-arm study [17]. All the included trials
compared epoetin HX575 to epoetin alpha. Two
out of the three studies evaluated intravenous
administration of HX575 [16,17]. One studyeference.
Figure 3 Mean epoetin dose used in studies comparing epoetin zeta and reference epoetins excluding the study by Wizemann et al.
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was conducted in stage III to IV CKD patients [15].
Two RCTs involving epoetin theta were identified
[18,19]. No studies were excluded. Both studies
compared epoetin theta to epoetin beta. One trial
evaluated intravenous administration in hemodialysis
patients [19] and the other trial evaluated the
subcutaneous route in patients with CKD not yet
receiving dialysis [18].
2. Risk of bias in included studies
Of the five epoetin zeta studies, allocation
concealment was adequate in two (40%) studies
[8,11], only three (60%) studies blinded participants
and investigators [8,9,11], and per protocol analyses
were used for efficacy analysis in the epoetin zeta
RCTs [8,9,11]. The percentage of patients lost to
follow-up ranged from 0% to 9.9% [8-12].
For the HX 575 studies, allocation concealment
was unclear and participants and investigators were
blinded in two out of three studies [15,16]; the
third study was an unblinded prospective single-
arm study [17]. An intention to treat (ITT) analysis
was used in one study [17] while the other two
studies used ITT analysis for safety data [15,16].
The percentage of patients lost to follow-up was
reported in two studies to be 15.7% and 17.8%
[15,16]. The percentage of patients lost to follow-up
was not reported in the INJ-17 study since the
study was stopped early [16].
For the two epoetin theta studies, allocation
concealment and blinding of participants and
investigators were adequate in both (100%) studies,
and an ITT analysis was used for safety analysis andFigure 4 Mean epoetin dose used in studies comparing HX575 and refeper protocol analysis was used for efficacy data
[18,19]. The number of patients lost to follow-up
was 0/288 and 1/270. Of note, the EMA guidelines
recommend the per protocol analysis as the primary
analysis in equivalence/non-inferiority trials. ITT
analyses are considered as sensitivity analysis and
were performed for all clinical trials.
3. Effects of interventions
There were no significant differences in the results
of analyses performed using random and fixed
effects models. The results presented below refer to
those obtained using a random effects model.
Subgroup analyses were not performed as the small
number of patients and studies made the power of
these analyses too small.i. Mean epoetin dose used1. Epoetin zetarenNo statistically significant differences were found
between the mean epoetin dose. The pooled mean
dose difference was 7.36 IU/kg/week (95% CI −2.12,
16.83); p = 0.13 (Figure 2).
Of note, three of the four studies showed that a
higher dose was required with epoetin zeta
compared with epoetin alpha to maintain similar
hemoglobin levels [8-10], although this finding was
not statistically significant in any of the studies.
The remaining study was a crossover study by
Wizemann et al. that accounted for 45% of the
weighted result [11]. The outcomes from this study
were measured during the treatment phase
immediately after the switch-over and the concernsce epoetin alpha.
Figure 5 Mean epoetin dose used in studies comparing epoetin theta and reference epoetin beta.
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treatment phase cannot be discounted. The
application to the EMA provided additional analyses,
including a comparison of hemoglobin values and
epoetin doses over the last 4 weeks of each
treatment period, as an attempt to minimise carry
over effects from previous epoetin treatment. The
equivalence margins were met with this new
post-hoc analysis according to the EMA Scientific
Report, but no details were given in the report that
could be included in our meta-analysis [20]. When
we excluded the Wizemann study because of the
cross-over design, the pooled mean dose was
13 IU/kg/week (95% CI 0.57, 26); p = 0.04 (Figure 3)
higher in the epoetin zeta arm.
2. HX 575
No statistically significant differences were found
between the mean epoetin doses used, which was
3.3 IU/kg/week (95% CI −4.0, 11); p = 0.38 (Figure 4).
3. Epoetin theta
No statistically significant differences were found between
the mean epoetin doses used, which was −1.3 IU/kg/
week (95% CI −8.7, 6.1); p = 0.73 (Figure 5).ii. Mean hemoglobin levels1. Epoetin zetaFigA statistically significant difference in mean
hemoglobin level was achieved, with the control
group having a higher mean haemoglobin level than
the epoetin zeta group by 0.12 g/dL (or 1.2 g/L)
(p = 0.03) (Figure 6). However, the absolute
difference is small, and is unlikely of clinical
importance.ure 6 Mean hemoglobin levels achieved in studies comparing epoet2. HX575
None of the HX 575 studies used mean hemoglobin
level as a study endpoint. However, , the mean
hemoglobin levels for the Haag-Weber et al. 2009
study were included in the EMA application and
varied between 11.6 to 11.9 g/dL (or 116 to 119 g/L)
for the HX575 group and 11.7 to 12.1 g/dL (or 117
to 121 g/L) for the reference group over the course
of the study [21]. The authors of the 3 studies were
contacted but did not provide further information;
therefore, a pooled analysis could not be performed.
3. Epoetin theta
Mean difference in hemoglobin level was −0.01 g/dL
(95% CI −0.18, 0.17) or −0.1 g/L (95% CI −1.8, 1.7),
p = 0.95 (Figure 7).iii. Mean absolute change in hemoglobin1. HX575
The mean absolute change in hemoglobin levels between
the screening period and the evaluation period was re-
ported in two HX 575 studies. An equivalence margin of ±
0.5 g/dl (or ± 5 g/L) in hemoglobin was chosen for the
demonstration of comparable efficacy. As shown in Figure 8,
the CI is within the predefined equivalence margin.
4. Safety dataI. Clinical trials1. Epoetin zetain zThe presence of anti-erythropoietin antibodies was
found at the screening phase but no cases of PRCAeta and reference epoetins. Note: unit g/L = 10 x g/dL.
Figure 7 Mean hemoglobin levels achieved in studies comparing epoetin theta and reference epoetin beta. Note: unit g/L = 10 x g/dL.
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difference in mortality between groups [8,9,11]. With
regards to toxicity, similar rates of adverse effects were
reported compared with the reference biologic [8-12].
2. HX575
Subcutaneous administration of HX575 was linked
to two cases of PRCA [16]; as such, HX575 is not
approved for subcutaneous administration in people
with chronic renal failure in Europe [21]. In
addition, no study found a difference in mortality
between the groups [15-17]. With regards to
toxicity, similar rates of adverse effects were
reported compared with the reference biologic, e.g.,
headache, hypertension, thrombosis [15-17].
3. Epoetin theta
No cases of anti-erythropoietin antibodies or PRCA
were reported [18,19] nor was there a difference in
mortality rates [18,19]. With regards to toxicity,
similar rates of adverse effects were reported
compared to the reference biologic (headache,
hypertension, thrombosis [18,19].II. European pharmacovigilance data
EudraVigilance is a system designed to collect reports
of suspected side effects and is used to evaluate the ben-
efits and risks of a medication during its development
and for monitoring its safety following market authorisa-
tion in the European Economic Area (EEA) [22]. Pharma-
ceutical companies that hold the marketing authorisation
of a medication as well as national medicines regulatory
authorities are legally required to submit reports ofFigure 8 Mean absolute change in hemoglobin levels in studies comp
x g/dL.suspected side effects that occurred in the EEA to Eudra-
Vigilance. This includes reports received from healthcare
professionals and patients. The pharmaceutical companies
are also required to provide information on all serious un-
expected adverse drug reactions that occurred in non-
EEA countries where they hold a marketing authorization.
Table 3 summarizes all the immunological and cardio-
vascular serious adverse drug reactions reported in Eudra-
Vigilance as of January 1st 2014 for the biosimilar epoetins
currently on the EU market. Note that each case reported
may contain one or multiple suspected ADRs and that the
total number of cases represents the total number of re-
ports submitted to EudraVigilance, for a specific marketed
biosimilar.
Discussion
This literature review found no clinically important differ-
ences in efficacy between the currently available SEB
epoetins (epoetin zeta, HX575 and epoetin theta) and the
reference ESA (epoetin alpha, epoetin beta and darbepoe-
tin). However, some limitations related to the studies in-
volving epoetin zeta should be noted. The Wizemann
study [11], which accounts for 45.4% of the weighted
pooled result, did not allow enough time for dose titration
to achieve steady state in a crossover design. In addition,
the investigators claimed that there was higher protein
content due to overfilling (9% over the labelled amount of
protein) noted with epoetin alpha compared with about
1% with epoetin zeta [20]. However, all syringes remained
within the 80 to 125% of the stated dose allowed with the
European Pharmacopoeia monograph for erythropoietin.
The applicant used a correction factor and providedaring HX575 and reference epoetin alpha. Note: unit g/L = 10
Table 3 Summary of the serious ADRs reported in
EudraVigilance database (as per January 2014) [22]
Active ingredient Brand name Serious ADR reports
HX 575 Abseamed® 10 cases total
1 case of PRCA
1 case of anemia
2 cases of decreased hemoglobin
2 cases of convulsion/epilepsy
1 case of DVT
Binocrit® 36 cases in total
1 case of anemia
2 cases of PRCA
4 cases of decreased hemoglobin
1 case of retinal artery occlusion
3 cases of chest pain
2 cases of pulmonary embolism
2 cases of hypertension
1 case of angiopathy
Epoetin Hexal® 4 cases in total
3 cases of decreased hemoglobin
1 case of PRCA
1 case of heart failure
Epoetin zeta Retacrit® 39 cases in total
1 case of anemia
2 cases of decreased hemoglobin
2 cases of myocardial infarction
4 cases of death
2 cases of drug ineffectiveness
1 case of stroke
1 case of convulsion
1 case of carotid artery stenosis
1 case of pulmonary embolism
1 case of hypertensive crisis
2 cases of thrombosis
Silapo® 6 cases in total
1 case of PRCA
1 case of deceased hemoglobin
2 cases of drug ineffectiveness
1 case of hypertension crisis
Epoetin theta Eporatio® 7 cases in total
3 cases of PRCA
1 case of anemia
1 case of decreased hemoglobin
1 case of angina
1 case of epilepsy
Table 3 Summary of the serious ADRs reported in
EudraVigilance database (as per January 2014) [22]
(Continued)
3 cases of drug ineffectiveness
Biopoin® 1 case in total
1 case of PRCA
ADRs = Adverse drug reactions; PRCA = Pure red cell aplasia.
N.B.: Each reported case may contain one or multiple suspected ADRs. Only
ADRs commonly attributed to epoetin therapy are listed above.
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for inter-batch variability in bioactivity and protein con-
tent. With the introduction of a correction factor, the 95%
CI fell (−24, 17 IU/kg/week) in the Krivoshiev 2008 study,
but the CI widened (3.1-14 IU/kg/week) in the Wizemann
study [20]. The difference in syringe content may be ex-
plained by the use of different bioassays for determination
of bioactivity for the test product (normocythaemic mouse
bioassay used in the EU) and the reference product (exhy-
poxic polycythaemic mouse bioassay used in the USA).
Lastly, the acceptable equivalence margin was modified
post-hoc from ± 14 IU/kg/week to ± 45 IU/kg/week by the
applicant to EMA due to a misreading of the European
Public Assessment Report (EPAR) that listed the no-effect
dosage of Dynepo® as 15 IU/kg given 3 times weekly but
was misread by the study investigators as once weekly.
This newly proposed acceptance range was supported by
the literature, accepted by the EMA and deemed clinically
unimportant. The upper limit of the CI for the dose dif-
ference is 17 IU/kg/week if the Wizemann study was in-
cluded compared with 26 IU/kg/week if the Wizemann
study was not included. The financial implication of a pos-
sible dose difference can be large when summed over pop-
ulations and over years and should be considered by those
who negotiate contracts for payers. The financial impact
analysis is illustrated in the Tornado diagram in the paper
by Tsao N et al. [23].
As for HX575, the mean absolute change in hemoglo-
bin was statistically significant in favour of the control
group [15]. However, it is within the pre-defined equiva-
lence margin. Another study in healthy volunteers ran-
domized to receive HX575 or Epogen® also pointed to
this possible difference in efficacy [24]. This study deter-
mined that the two products were bioequivalent, even
though HX575 exposure was approximately 10% lower
[24]. This difference is difficult to ascertain since the infor-
mation is quite sparse. The ongoing trials with HX575
should help elucidate this issue.
In terms of toxicity, this review found no differences
between biosimilar epoetins (epoetin zeta, HX575 and
epoetin theta) and the reference epoetin with the excep-
tion of two cases of PRCA, one confirmed and one pos-
sible, reported with the subcutaneous administration of
HX575 [16]. These cases were attributed to the increased
Marin et al. Canadian Journal of Kidney Health and Disease  (2014) 1:34 Page 12 of 13concentration of tungsten in the prefilled syringes causing
denaturation of epoetin molecules and subsequent for-
mation of immunogenic aggregates [16]. Subcutaneous
administration is currently not an approved route of ad-
ministration for HX575 in Europe [21] but there are on-
going trials to further evaluate the safety of subcutaneous
administration of HX575. Since its launch in March 2012,
patient exposure to HX575 has been estimated to be
134,928 patients-years, without any indication of increased
immunogenicity [1,25]. Subcutaneous administration for
both epoetin zeta (n = 232) and epoetin theta (n = 193)
have been studied and no increased risk of PRCA have
been found.
Conclusion
Based on currently-available published information, epoetin
zeta and epoetin theta appear to have similar efficacy to
that of the reference ESA and no evidence of an increased
risk of PRCA or adverse reactions. Although not considered
clinically important or statistically significant in the clinical
trials, the higher dose requirement for epoetin zeta to
achieve target hemoglobin should be noted. Further
studies should be conducted to confirm the dose differ-
ence with epoetin zeta, and pharmacoeconomic studies
should be conducted to examine financial implications.
The current available evidence is inadequate and further
studies are required to clarify the risk of subcutaneous ad-
ministration of HX575. Furthermore, post-marketing sur-
veillance is needed to provide a more precise estimate of
PRCA frequency and to establish the overall adverse reac-
tion profile of all epoetin SEBs in clinical practice.
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